Cited 0 times in
Association between PD-L1 expression and 18 F-FDG uptake in ovarian cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강원준 | - |
dc.contributor.author | 김상운 | - |
dc.contributor.author | 김성훈 | - |
dc.contributor.author | 김영태 | - |
dc.contributor.author | 이정윤 | - |
dc.contributor.author | 정용휴 | - |
dc.contributor.author | 황상현 | - |
dc.date.accessioned | 2021-12-28T17:07:24Z | - |
dc.date.available | 2021-12-28T17:07:24Z | - |
dc.date.issued | 2021-04 | - |
dc.identifier.issn | 0914-7187 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/186947 | - |
dc.description.abstract | Objective: Immunotherapy for programmed cell death 1 (PD-1) and its ligand, PD-L1, has been considered an effective treatment for ovarian cancer. 18F-labeled fluoro-2-deoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is a widely used noninvasive imaging tool for diagnosing several cancers. In this study, we investigated the association between PD-L1 expression and the maximum standardized uptake value (SUVmax) using 18F-FDG PET/CT. Methods: We retrospectively analyzed clinical data of patients with ovarian cancer who underwent 18F-FDG PET/CT. Patients were categorized into two groups according to PD-L1 expression results. The relationship between clinicopathological characteristics of patients with ovarian cancer and PD-L1 expression was examined. Results: SUVmax was significantly higher in PD-L1-positive tumors than in PD-L1-negative tumors (16.1 ± 5.2 and 12.7 ± 7.0, respectively; p = 0.026). There were no significant differences in age, histologic type, and tumor grade between the PD-L1-negative and PD-L1-positive groups. The receiver operating characteristic curve analysis demonstrated that the highest accuracy (61.8%) for predicting PD-L1 expression was obtained with an SUVmax cutoff value of 10.5. Conclusion: There was a significant correlation between 18F-FDG uptake and PD-L1 expression, suggesting a role of 18F-FDG PET/CT in selecting ovarian cancer candidates for anti-PD-L1 antibody therapy. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer Japan | - |
dc.relation.isPartOf | ANNALS OF NUCLEAR MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | B7-H1 Antigen / analysis* | - |
dc.subject.MESH | B7-H1 Antigen / genetics | - |
dc.subject.MESH | B7-H1 Antigen / metabolism | - |
dc.subject.MESH | Biological Transport | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorodeoxyglucose F18 / chemistry* | - |
dc.subject.MESH | Fluorodeoxyglucose F18 / metabolism | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Multivariate Analysis | - |
dc.subject.MESH | Ovarian Neoplasms / classification | - |
dc.subject.MESH | Ovarian Neoplasms / diagnosis* | - |
dc.subject.MESH | Positron Emission Tomography Computed Tomography | - |
dc.subject.MESH | Radiopharmaceuticals / chemistry* | - |
dc.subject.MESH | Radiopharmaceuticals / metabolism | - |
dc.subject.MESH | Retrospective Studies | - |
dc.title | Association between PD-L1 expression and 18 F-FDG uptake in ovarian cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Nuclear Medicine (핵의학교실) | - |
dc.contributor.googleauthor | Yun Jung Choi | - |
dc.contributor.googleauthor | KwanHyeong Jo | - |
dc.contributor.googleauthor | Sang Hyun Hwang | - |
dc.contributor.googleauthor | YongHyu Jeong | - |
dc.contributor.googleauthor | Jung-Yun Lee | - |
dc.contributor.googleauthor | Sunghoon Kim | - |
dc.contributor.googleauthor | Sang Wun Kim | - |
dc.contributor.googleauthor | Young Tae Kim | - |
dc.contributor.googleauthor | Won Jun Kang | - |
dc.identifier.doi | 10.1007/s12149-020-01571-7 | - |
dc.contributor.localId | A00062 | - |
dc.contributor.localId | A00526 | - |
dc.contributor.localId | A00595 | - |
dc.contributor.localId | A00729 | - |
dc.contributor.localId | A04638 | - |
dc.contributor.localId | A05554 | - |
dc.contributor.localId | A05953 | - |
dc.relation.journalcode | J00167 | - |
dc.identifier.eissn | 1864-6433 | - |
dc.identifier.pmid | 33656683 | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs12149-020-01571-7 | - |
dc.subject.keyword | FDG | - |
dc.subject.keyword | Ovarian cancer | - |
dc.subject.keyword | PD-L1 | - |
dc.subject.keyword | PET/CT | - |
dc.contributor.alternativeName | Kang, Won Jun | - |
dc.contributor.affiliatedAuthor | 강원준 | - |
dc.contributor.affiliatedAuthor | 김상운 | - |
dc.contributor.affiliatedAuthor | 김성훈 | - |
dc.contributor.affiliatedAuthor | 김영태 | - |
dc.contributor.affiliatedAuthor | 이정윤 | - |
dc.contributor.affiliatedAuthor | 정용휴 | - |
dc.contributor.affiliatedAuthor | 황상현 | - |
dc.citation.volume | 35 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 415 | - |
dc.citation.endPage | 420 | - |
dc.identifier.bibliographicCitation | ANNALS OF NUCLEAR MEDICINE, Vol.35(4) : 415-420, 2021-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.